The Brain Aneurysm Foundation (BAF) has announced the appointment of Joseph P Caruso to its board of directors, with Caruso commencing a three-year term on the board this month.
A BAF press release notes that Caruso has decades of business experience and a distinguished career in the medical device field, having spent more than 20 years at Palomar Medical Technologies—a publicly traded medical laser company—where he was president, chief executive officer (CEO), and board chairman. He brings the BAF broad executive management, operational, financial, administrative and general management experience, the release adds, also stating that Caruso remains active on the boards of both public and private medical device companies.
Joseph P Caruso and his wife, Lynne, have led advocates and fundraisers for brain aneurysm research, becoming active in foundation programmes following the death of their 31-year-old daughter Katelyn in 2023. In her memory, they established Katelyn’s Crew—an organisation that raises awareness for the disease and now funds two BAF research chairs, supporting innovative studies at Mass General Brigham (Boston, USA) and the University of Pittsburgh (Pittsburgh, USA).
“The Carusos have been tireless in their work to create awareness, and to fund research that can accelerate new treatments and interventions for brain aneurysms,” said Christine Buckley, executive director of the BAF. “Joe’s experience as a healthcare leader will further our efforts to educate physicians, first responders, and those who may be at risk of rupture, about the signs and symptoms while supporting our work with payers and lawmakers to ensure those at risk can have access to life-saving brain scans.”
“I look forward to collaborating with Christine, board chair Tom Tinlin and members of the organisation, and the wider community, as we seek solutions to prevent these avoidable ruptures,” Caruso added. “We are on the verge of significant advancements to better detect and predict the potential ruptures, and—with additional resources—we will be able to expedite life-saving treatments. Having experienced the loss of a loved one to a brain aneurysm, my primary objective is to work as swiftly as possible to prevent other families from enduring the devastating effects of this condition.”
In a separate press release this week, the BAF also announced that executive director Buckley will speak at the 2025 International Stroke Conference (ISC; 5–7 February, Los Angeles, USA) via a presentation titled, “Understanding the patient’s perspective: navigating the fear of a ‘ticking bomb’ inside my head”.
“It is an honour to represent the voice of the millions of patients, families and caregivers impacted by this devastating condition, and to share their stories with leading physicians in the field,” Buckley commented.
